{"title":"177lu -利妥昔单抗的制备及与131i -利妥昔单抗氯胺- t法放射性标记的比较","authors":"F. J. Daha, S. Rasaneh, S. Zahabi","doi":"10.5812/JCRPS.87181","DOIUrl":null,"url":null,"abstract":"Background: Themainpurposeof radioimmunotherapyisdeliveredlethaldosetothetumorcellswhichdependsontheimmuno-logical and pharmacological of the antibody (Ab) property and the conjugated radionuclide characteristics. Objectives: The aim of this study is preparation of DOTA-Rituximab complex and radiolabeling with Lu-177 and comparison with the results of 131 I-Rituximab radiolabed with Chloramine-T method that was obtained before. Methods: The number of chelator molecules (DOTA) attached to the DOTA-Rituximab complex was determined by Arsenazo III reagent. After radiolabeling with Lu -177, the stability in normal saline and the biodistribution in the healthy mice was evaluated. The Immunoreactivity of Ab was checked on Raji cell lines and the results were compared with 131 I-Rituximab. Results: Each 300 µ g of antibody was labeled with 6 mCi Lu-177. After 48 hours, 82% of the radiolabeled antibody was stable and about 18% of the radiotracer was in the blood. The immunoreactivity was calculated 85% ± 2%. Conclusions: TheresultsshowedthatradiolabelingwithLu-177wasdonewithhigheryieldthaniodine-131andtheproducedradio-pharmacy has more stability and immunoreactivity. The biodistribution results were acceptable in both radiopharmacy.","PeriodicalId":254271,"journal":{"name":"Journal of Clinical Research in Paramedical Sciences","volume":"49 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Preparation of 177Lu-Rituximab and Comparison with 131I-Rituximab Radiolabeled with Chloramine-T Method\",\"authors\":\"F. J. Daha, S. Rasaneh, S. Zahabi\",\"doi\":\"10.5812/JCRPS.87181\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Themainpurposeof radioimmunotherapyisdeliveredlethaldosetothetumorcellswhichdependsontheimmuno-logical and pharmacological of the antibody (Ab) property and the conjugated radionuclide characteristics. Objectives: The aim of this study is preparation of DOTA-Rituximab complex and radiolabeling with Lu-177 and comparison with the results of 131 I-Rituximab radiolabed with Chloramine-T method that was obtained before. Methods: The number of chelator molecules (DOTA) attached to the DOTA-Rituximab complex was determined by Arsenazo III reagent. After radiolabeling with Lu -177, the stability in normal saline and the biodistribution in the healthy mice was evaluated. The Immunoreactivity of Ab was checked on Raji cell lines and the results were compared with 131 I-Rituximab. Results: Each 300 µ g of antibody was labeled with 6 mCi Lu-177. After 48 hours, 82% of the radiolabeled antibody was stable and about 18% of the radiotracer was in the blood. The immunoreactivity was calculated 85% ± 2%. Conclusions: TheresultsshowedthatradiolabelingwithLu-177wasdonewithhigheryieldthaniodine-131andtheproducedradio-pharmacy has more stability and immunoreactivity. The biodistribution results were acceptable in both radiopharmacy.\",\"PeriodicalId\":254271,\"journal\":{\"name\":\"Journal of Clinical Research in Paramedical Sciences\",\"volume\":\"49 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Research in Paramedical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/JCRPS.87181\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Research in Paramedical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/JCRPS.87181","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
背景:放射免疫治疗的主要目的是向肿瘤细胞递送致死剂量,这取决于抗体(Ab)的免疫学和药理学性质以及缀合放射性核素的特性。目的:制备dota -利妥昔单抗配合物并用Lu-177进行放射性标记,并与之前获得的131 i -利妥昔单抗氯胺- t法放射性标记结果进行比较。方法:采用偶氮胂试剂测定DOTA-利妥昔单抗配合物的螯合剂分子(DOTA)数量。用Lu -177放射性标记后,评价其在生理盐水中的稳定性和在健康小鼠体内的生物分布。在Raji细胞株上检测Ab的免疫反应性,并与131 i -利妥昔单抗进行比较。结果:每300µg抗体用6 mCi Lu-177标记。48小时后,82%的放射性标记抗体是稳定的,约18%的放射性示踪剂在血液中。免疫反应性计算为85%±2%。结论:用铀-177进行放射性标记,产率较高,制备的放射性药物具有较好的稳定性和免疫反应性。两种放射药理学的生物分布结果均可接受。
Preparation of 177Lu-Rituximab and Comparison with 131I-Rituximab Radiolabeled with Chloramine-T Method
Background: Themainpurposeof radioimmunotherapyisdeliveredlethaldosetothetumorcellswhichdependsontheimmuno-logical and pharmacological of the antibody (Ab) property and the conjugated radionuclide characteristics. Objectives: The aim of this study is preparation of DOTA-Rituximab complex and radiolabeling with Lu-177 and comparison with the results of 131 I-Rituximab radiolabed with Chloramine-T method that was obtained before. Methods: The number of chelator molecules (DOTA) attached to the DOTA-Rituximab complex was determined by Arsenazo III reagent. After radiolabeling with Lu -177, the stability in normal saline and the biodistribution in the healthy mice was evaluated. The Immunoreactivity of Ab was checked on Raji cell lines and the results were compared with 131 I-Rituximab. Results: Each 300 µ g of antibody was labeled with 6 mCi Lu-177. After 48 hours, 82% of the radiolabeled antibody was stable and about 18% of the radiotracer was in the blood. The immunoreactivity was calculated 85% ± 2%. Conclusions: TheresultsshowedthatradiolabelingwithLu-177wasdonewithhigheryieldthaniodine-131andtheproducedradio-pharmacy has more stability and immunoreactivity. The biodistribution results were acceptable in both radiopharmacy.